Company profile: Alligator Bioscience
1.1 - Company Overview
Company description
- Provider of antibody-based immunotherapies for cancer, including next-generation CD40 agonists and bispecific CD40-targeting antibodies, developed using its FIND® (Fragment INduced Diversity) protein optimization technology, and discovering and developing drug candidates up to phase IIa clinical studies.
Products and services
- Bispecific CD40-targeting antibodies: Custom-engineered, antibody-based components that concurrently bind CD40 and a second antigen to amplify cancer immunotherapy efficacy through dual-target engagement
- FIND® (Fragment INduced Diversity): Proprietary protein optimization technology that engineers and enhances antibody-based immunotherapies specifically for cancer treatment, improving therapeutic candidate properties via fragment-induced diversity
- Next-generation CD40 agonists: Therapeutic-grade, antibody-based products that activate the CD40 receptor to intensify immune responses against cancer, engineered for potent CD40 pathway engagement in oncology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alligator Bioscience
SmartPharm
HQ: United States
Website
- Description: Provider of second-generation gene-encoded therapeutics, offering Gene MAbs, a DNA-based platform producing neutralizing antibodies against SARS-CoV-2 in muscle tissue for scalable, cost-effective COVID-19 protection, non-viral gene therapy for enzyme replacement in lysosomal storage diseases, and gene-encoded biologics to preserve and restore cell and tissue viability after acute myocardial infarction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SmartPharm company profile →
Novavax
HQ: United States
Website
- Description: Provider of vaccines and vaccine technologies for infectious diseases, including a recombinant nanoparticle COVID-19 vaccine with Matrix-M adjuvant; a Phase 2 COVID-influenza combination (CIC) vaccine; and the authorized R21/Matrix-M malaria vaccine. Also offers Matrix-M, a saponin-based adjuvant, and recombinant nanoparticle vaccine technology using engineered proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novavax company profile →
Human Genome Sciences
HQ: United States
Website
- Description: Provider of global healthcare focused on helping people do more, feel better, and live longer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Human Genome Sciences company profile →
BioNTech
HQ: Germany
Website
- Description: Provider of next-generation immunotherapies for cancer and infectious diseases, including mRNA-based drugs to encode antigens, neoantigens, cytokines and antibodies; engineered cell therapies (CAR-T and TCR); protein therapeutics such as antibodies, bispecifics and antibody-drug conjugates; and small-molecule immunomodulators. Also conducts clinical trials and advances a pipeline of investigational vaccines and immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioNTech company profile →
Sutro Biopharma
HQ: United States
Website
- Description: Provider of protein therapeutics leveraging OCFS and XpressCF cell-free protein synthesis, with an ADC pipeline: luveltamab tazevibulin (luvelta) targeting folate receptor alpha in clinical studies for platinum-resistant ovarian cancer; STRO-003 (ROR1-targeting) under a global licensing agreement with potential milestones and royalties; STRO-004 (tissue factor-targeting) planned for 2025 IND; plus sustainability efforts and a summer internship program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sutro Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alligator Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alligator Bioscience
2.2 - Growth funds investing in similar companies to Alligator Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alligator Bioscience
4.2 - Public trading comparable groups for Alligator Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →